Nuvilex Inc (NVLX) 0.3350 $NVLX
Nuvilex's Pancreatic Cancer Treatment Continues to Outperform Big Pharma Heading Into Late Phase Trials
Marketwire - Wed May 07, 8:04AM CDT
Nuvilex, Inc.'s (OTCQB: NVLX) advanced pancreatic cancer treatment first outperformed historical data presented by the NYSE's Eli Lilly and its FDA approved pancreatic cancer drug Gemzar(R), then it was NASDAQ's Celgene and its recently FDA approved treatment of Abraxane(R) plus gemcitabine, and now the latest treatment that Nuvilex's Cell-in-a-Box(R) combined with the anticancer drug ifosfamide outperforms is NASDAQ-listed Merrimack Pharmaceuticals and its treatment, the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin.
Brendan O'Brien Named to Strategic Advisory Board of Provectus Biopharmaceuticals, Inc.
ACCESSWIRE - Tue May 06, 9:38AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT), a biotech company specializing in developing oncology and dermatology therapies, announced today the appointment of Brendan O'Brien to its strategic advisory board.
Nuvilex, Inc.'s Cell-in-a-Box Treatment Called Magic Bullets of 21st Century by World Renowned Oncologist
Marketwire - Mon May 05, 8:03AM CDT
Nuvilex, Inc. (OTCQB: NVLX) continued to awe investors last week with yet another marquee name that has agreed to work with its pancreatic cancer treatment of Cell-in-a-Box(R) combined with the anticancer drug ifosfamide. As the company heads into late phase clinical trials, it will do so with both a familiar name to the treatment and to the field of oncology in Dr. Matthias Lohr of the famed Karolinska Institute in Stockholm, Sweden.
Intelligent Living Builds a Diverse Cannabis Brand
ACCESSWIRE - Thu May 01, 10:24AM CDT
Whitefish, MT / May 1, 2014 / The U.S. medical cannabis market is expected to grow from $1.7 billion in 2011 to $9 billion by 2016, according to a 2011 report from See Change Strategy, while recreational legalization in Colorado and Washington could accelerate that growth. Investors have a number of different ways to gain exposure to the industry, and they may be wise to seek out the most diversified opportunities to mitigate risk in such a new business climate.
Nuvilex Adds World Renowned Oncologist and Gastroenterologist to Play Major Role in Late Phase Clinical Trial
GlobeNewswire - Thu May 01, 9:40AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that world renowned oncologist and gastroenterologist Professor Dr. Matthias Lohr of the famed Karolinska Institute in Stockholm, Sweden, has agreed to play a major role in Nuvilex's Phase 2b clinical trial in pancreatic cancer to be conducted in Australia, as well as other clinical studies and trials in which Nuvilex will be involved. Dr. Lohr served as Principal Investigator for the previous Phase 1/2 clinical trials that employed Nuvilex's pancreatic cancer treatment.
Fed Shows Confidence in Market with Cut in Bond Buying Stimulus
PR Newswire Europe - Thu May 01, 6:33AM CDT
LONDON, May 1, 2014 /PRNewswire/ --
GrowLife Inc.'s Shares Lose Value after Trading Resumes
ACCESSWIRE - Wed Apr 30, 2:04PM CDT
GrowLife Inc.'s (OTCBB: PHOT) share value is substantially less than it was on the day the Security and Exchange Commission (SEC) suspended the trading of its shares from Apr. 10 through Apr. 24.
Medical Marijuana Sciences' Scientific Advisory Board Chairman Dr. Mark L. Rabe Educates Professional Fiduciaries on the Benefits of Medical Marijuana
GlobeNewswire - Mon Apr 28, 10:06AM CDT
Medical Marijuana Sciences, Inc. (MMS), a subsidiary of Nuvilex, Inc. (OTCQB:NVLX), a clinical stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Mark L. Rabe, MD, ABIHM, the Scientific Advisory Board Chairman of MMS, addressed conservators, guardians and trustees at the Professional Fiduciary Association of California (PFAC) Educational Conference in San Diego as part of the Medical Marijuana Education Session that occurred at the PFAC Educational Conference on April 25, 2014, where he discussed the medical benefits of the components of Cannabis (Marijuana).
Novagent Corp. Acquires Proprietary and Intellectual Property Rights to Revolutionary Cannabis Growing Light Device
ACCESSWIRE - Sun Apr 27, 11:33PM CDT
Novagant Corp. (OTC: NVGT) has acquired full proprietary and intellectual property rights to a newly invented light device that can provide programmable and adjustable lighting intended for the indoor growth and cultivation of plants. The light device will have a specialization for cannabis plants. This is an invention that will have one of the best pound per watt yield in the industry.
Medical Marijuana Sciences' Scientific Advisory Board Chairman Dr. Mark L. Rabe Presents to Pain Medicine and Other Physicians at the University of California San Diego
GlobeNewswire - Fri Apr 25, 9:43AM CDT
Medical Marijuana Sciences, Inc. (MMS), a subsidiary of Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Mark L. Rabe, MD, ABIHM, the Scientific Advisory Board Chairman of MMS, delivered a "Pain Medicine Grand Rounds" presentation to pain specialists and other physicians at the University of California, San Diego (UCSD) that dealt with the medicinal properties of constituents of Cannabis (marijuana) that are known as cannabinoids.
Super Stock Profits Top Five Small Cap Focus List: Creative Edge Nutrition, Inc. Minerco Resources, Inc. Terra Tech Corporation, MedBox, Inc. Nuvilex, Inc.
PR Newswire Europe - Tue Apr 22, 9:05AM CDT
LONDON, April 22, 2014 /PRNewswire/ --
Cannabis Sector Appears To Stabilize With New Advancements - Company Enters JV for 70 Acre Hemp Farm
PR Newswire - Tue Apr 22, 8:02AM CDT
Marijuana companies acquire resources with expansion in sight: Polaris International Holdings, Inc. (OTC: PIHN), Tranzbyte Corporation (OTC: ERBB), Planda (OTC: PLPL), Nuvilex, Inc. (OTC: NVLX), Latteno Food Corp. (OTC: LATF) and MediSwipe, Inc. (OTC: MWIP)
Nuvilex, Inc. Applying for Orphan Drug Status to Market Pancreatic Cancer Treatment Without Competition
Marketwire - Tue Apr 22, 7:45AM CDT
When Nuvilex, Inc. (OTCQB: NVLX) named Clinical Network Services (CNS) as the Contract Research Organization (CRO) for its late phase clinical trials in advanced pancreatic cancer, the company also stated it will apply for "Orphan Drug" status. This is a designation that will allow Nuvilex to exclusively market its pancreatic cancer treatment using the Cell-in-a-Box(R) technology combined with the anticancer drug ifosfamide. Treatments for pancreatic cancer engender an Orphan Drug designation in most countries and that alone enables companies receiving the status to sell their approved treatment without competition for an additional 7 years in the US and 10 years in Europe.
Nuvilex Inc. Could Obtain FDA Accelerated Approval after Phase 2b Clinical Trial
ACCESSWIRE - Mon Apr 21, 9:00AM CDT
Nuvilex Inc.'s (OTCQB: NVLX) announced it could obtain an accelerated FDA approval of its pancreatic cancer treatment if it can produce the same strong results in an announced Phase 2b clinical trial.
Frozen Food Gift Group Becomes APT Group Inc.
ACCESSWIRE - Thu Apr 17, 9:00AM CDT
On Apr. 16, APT Group Inc. (OTCQB: FROZ) stock volume soared, with 92,118,453 shares changing hands, nearly twice its three-month average volume of 57,140,919 shares.
Nuvilex Contracts With Clinical Network Services Pty Ltd for Late-Phase Clinical Trials in Pancreatic Cancer
GlobeNewswire - Tue Apr 15, 8:00AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has contracted Clinical Network Services Pty Ltd (CNS), a fully integrated drug development company based in Australia, New Zealand and the United Kingdom, to handle every aspect of Nuvilex's late-phase clinical trials in pancreatic cancer as Nuvilex's Contract Research Organization (CRO). The trials, which will focus on treatment for advanced stage pancreatic cancer, will involve Nuvilex's pancreatic cancer treatment (a combination of the proprietary "Cell in-a-Box" live-cell encapsulation technology and the cancer drug ifosfamide) which has already proved effective in early stage trials.
Nuvilex, Inc. Analyst Report: Potentially Revolutionary Technology Positions Biopharmaceutical Firm as a Cancer Market Competitor - Fundamentals Need to Catch up With Expectations by Brokerbank Securities, Inc.
PR Newswire - Tue Apr 15, 6:00AM CDT
Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biopharmaceutical competitor is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, called Cell-in-a-Box®. This unique technology is intended for use as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built.
Nuvilex's Pancreatic Cancer Treatment Continues to Outperform Big Pharma Heading Into Late Phase Trials
Marketwire - Wed May 07, 8:04AM CDT
Nuvilex, Inc.'s (OTCQB: NVLX) advanced pancreatic cancer treatment first outperformed historical data presented by the NYSE's Eli Lilly and its FDA approved pancreatic cancer drug Gemzar(R), then it was NASDAQ's Celgene and its recently FDA approved treatment of Abraxane(R) plus gemcitabine, and now the latest treatment that Nuvilex's Cell-in-a-Box(R) combined with the anticancer drug ifosfamide outperforms is NASDAQ-listed Merrimack Pharmaceuticals and its treatment, the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin.
Brendan O'Brien Named to Strategic Advisory Board of Provectus Biopharmaceuticals, Inc.
ACCESSWIRE - Tue May 06, 9:38AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT), a biotech company specializing in developing oncology and dermatology therapies, announced today the appointment of Brendan O'Brien to its strategic advisory board.
Nuvilex, Inc.'s Cell-in-a-Box Treatment Called Magic Bullets of 21st Century by World Renowned Oncologist
Marketwire - Mon May 05, 8:03AM CDT
Nuvilex, Inc. (OTCQB: NVLX) continued to awe investors last week with yet another marquee name that has agreed to work with its pancreatic cancer treatment of Cell-in-a-Box(R) combined with the anticancer drug ifosfamide. As the company heads into late phase clinical trials, it will do so with both a familiar name to the treatment and to the field of oncology in Dr. Matthias Lohr of the famed Karolinska Institute in Stockholm, Sweden.
Intelligent Living Builds a Diverse Cannabis Brand
ACCESSWIRE - Thu May 01, 10:24AM CDT
Whitefish, MT / May 1, 2014 / The U.S. medical cannabis market is expected to grow from $1.7 billion in 2011 to $9 billion by 2016, according to a 2011 report from See Change Strategy, while recreational legalization in Colorado and Washington could accelerate that growth. Investors have a number of different ways to gain exposure to the industry, and they may be wise to seek out the most diversified opportunities to mitigate risk in such a new business climate.
Nuvilex Adds World Renowned Oncologist and Gastroenterologist to Play Major Role in Late Phase Clinical Trial
GlobeNewswire - Thu May 01, 9:40AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that world renowned oncologist and gastroenterologist Professor Dr. Matthias Lohr of the famed Karolinska Institute in Stockholm, Sweden, has agreed to play a major role in Nuvilex's Phase 2b clinical trial in pancreatic cancer to be conducted in Australia, as well as other clinical studies and trials in which Nuvilex will be involved. Dr. Lohr served as Principal Investigator for the previous Phase 1/2 clinical trials that employed Nuvilex's pancreatic cancer treatment.
Fed Shows Confidence in Market with Cut in Bond Buying Stimulus
PR Newswire Europe - Thu May 01, 6:33AM CDT
LONDON, May 1, 2014 /PRNewswire/ --
GrowLife Inc.'s Shares Lose Value after Trading Resumes
ACCESSWIRE - Wed Apr 30, 2:04PM CDT
GrowLife Inc.'s (OTCBB: PHOT) share value is substantially less than it was on the day the Security and Exchange Commission (SEC) suspended the trading of its shares from Apr. 10 through Apr. 24.
Medical Marijuana Sciences' Scientific Advisory Board Chairman Dr. Mark L. Rabe Educates Professional Fiduciaries on the Benefits of Medical Marijuana
GlobeNewswire - Mon Apr 28, 10:06AM CDT
Medical Marijuana Sciences, Inc. (MMS), a subsidiary of Nuvilex, Inc. (OTCQB:NVLX), a clinical stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Mark L. Rabe, MD, ABIHM, the Scientific Advisory Board Chairman of MMS, addressed conservators, guardians and trustees at the Professional Fiduciary Association of California (PFAC) Educational Conference in San Diego as part of the Medical Marijuana Education Session that occurred at the PFAC Educational Conference on April 25, 2014, where he discussed the medical benefits of the components of Cannabis (Marijuana).
Novagent Corp. Acquires Proprietary and Intellectual Property Rights to Revolutionary Cannabis Growing Light Device
ACCESSWIRE - Sun Apr 27, 11:33PM CDT
Novagant Corp. (OTC: NVGT) has acquired full proprietary and intellectual property rights to a newly invented light device that can provide programmable and adjustable lighting intended for the indoor growth and cultivation of plants. The light device will have a specialization for cannabis plants. This is an invention that will have one of the best pound per watt yield in the industry.
Medical Marijuana Sciences' Scientific Advisory Board Chairman Dr. Mark L. Rabe Presents to Pain Medicine and Other Physicians at the University of California San Diego
GlobeNewswire - Fri Apr 25, 9:43AM CDT
Medical Marijuana Sciences, Inc. (MMS), a subsidiary of Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Mark L. Rabe, MD, ABIHM, the Scientific Advisory Board Chairman of MMS, delivered a "Pain Medicine Grand Rounds" presentation to pain specialists and other physicians at the University of California, San Diego (UCSD) that dealt with the medicinal properties of constituents of Cannabis (marijuana) that are known as cannabinoids.
Super Stock Profits Top Five Small Cap Focus List: Creative Edge Nutrition, Inc. Minerco Resources, Inc. Terra Tech Corporation, MedBox, Inc. Nuvilex, Inc.
PR Newswire Europe - Tue Apr 22, 9:05AM CDT
LONDON, April 22, 2014 /PRNewswire/ --
Cannabis Sector Appears To Stabilize With New Advancements - Company Enters JV for 70 Acre Hemp Farm
PR Newswire - Tue Apr 22, 8:02AM CDT
Marijuana companies acquire resources with expansion in sight: Polaris International Holdings, Inc. (OTC: PIHN), Tranzbyte Corporation (OTC: ERBB), Planda (OTC: PLPL), Nuvilex, Inc. (OTC: NVLX), Latteno Food Corp. (OTC: LATF) and MediSwipe, Inc. (OTC: MWIP)
Nuvilex, Inc. Applying for Orphan Drug Status to Market Pancreatic Cancer Treatment Without Competition
Marketwire - Tue Apr 22, 7:45AM CDT
When Nuvilex, Inc. (OTCQB: NVLX) named Clinical Network Services (CNS) as the Contract Research Organization (CRO) for its late phase clinical trials in advanced pancreatic cancer, the company also stated it will apply for "Orphan Drug" status. This is a designation that will allow Nuvilex to exclusively market its pancreatic cancer treatment using the Cell-in-a-Box(R) technology combined with the anticancer drug ifosfamide. Treatments for pancreatic cancer engender an Orphan Drug designation in most countries and that alone enables companies receiving the status to sell their approved treatment without competition for an additional 7 years in the US and 10 years in Europe.
Nuvilex Inc. Could Obtain FDA Accelerated Approval after Phase 2b Clinical Trial
ACCESSWIRE - Mon Apr 21, 9:00AM CDT
Nuvilex Inc.'s (OTCQB: NVLX) announced it could obtain an accelerated FDA approval of its pancreatic cancer treatment if it can produce the same strong results in an announced Phase 2b clinical trial.
Frozen Food Gift Group Becomes APT Group Inc.
ACCESSWIRE - Thu Apr 17, 9:00AM CDT
On Apr. 16, APT Group Inc. (OTCQB: FROZ) stock volume soared, with 92,118,453 shares changing hands, nearly twice its three-month average volume of 57,140,919 shares.
Nuvilex Contracts With Clinical Network Services Pty Ltd for Late-Phase Clinical Trials in Pancreatic Cancer
GlobeNewswire - Tue Apr 15, 8:00AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has contracted Clinical Network Services Pty Ltd (CNS), a fully integrated drug development company based in Australia, New Zealand and the United Kingdom, to handle every aspect of Nuvilex's late-phase clinical trials in pancreatic cancer as Nuvilex's Contract Research Organization (CRO). The trials, which will focus on treatment for advanced stage pancreatic cancer, will involve Nuvilex's pancreatic cancer treatment (a combination of the proprietary "Cell in-a-Box" live-cell encapsulation technology and the cancer drug ifosfamide) which has already proved effective in early stage trials.
Nuvilex, Inc. Analyst Report: Potentially Revolutionary Technology Positions Biopharmaceutical Firm as a Cancer Market Competitor - Fundamentals Need to Catch up With Expectations by Brokerbank Securities, Inc.
PR Newswire - Tue Apr 15, 6:00AM CDT
Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biopharmaceutical competitor is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, called Cell-in-a-Box®. This unique technology is intended for use as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built.
